Literature DB >> 28147358

Hematopoietic Stem Cell Transplantation in Crohn's Disease: State-of-the-Art Treatment.

C J Hawkey1.   

Abstract

Both autologous and allogeneic haemopoietic stem cell transplantation (HSCT) have been tried in Crohn's disease (CD). In allogeneic HSCT, the host bone marrow is ablated and replaced by bone marrow from a donor. This substitution of a genetically different bone marrow is effective in a number of conditions including those with an immunological basis such as CD. While the toxicity of allogeneic HSCT has precluded its uptake in idiopathic CD, there is interest in its utility in the management of early onset infantile (inflammatory bowel disease), which behaves as a monogenic disorder, with abnormalities of the interleukin 10 signalling system as the best recognized. In autologous HSCT, the patient's own stem cells are harvested before proceeding to lymphoablation and transplantation of the patient's own uncommitted stem cells, which generate an immune system with an altered T-cell repertoire. In a limited number of cases, this has led to substantial and prolonged remission tantamount to possible cure of CD. However, case series and controlled data from the Autologous Stem Cell International Crohn's Disease study suggest that although this method has its own advantages, most patients are still at risk of redeveloping CD, albeit with an arguably improved response to conventional treatment. The availability of new treatments for CD means that an HSCT is not a suitable treatment method for a majority of patients because of its greater toxicity, even though efficacy may be superior. Wider usage would depend upon the development of protocols that are safer and better targeted.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28147358     DOI: 10.1159/000449090

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  4 in total

1.  Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis.

Authors:  Pengcheng Zhang; Bing Liu
Journal:  Bone Marrow Transplant       Date:  2020-02-04       Impact factor: 5.483

Review 2.  Stem cell-based therapy for human diseases.

Authors:  Duc M Hoang; Phuong T Pham; Trung Q Bach; Anh T L Ngo; Quyen T Nguyen; Trang T K Phan; Giang H Nguyen; Phuong T T Le; Van T Hoang; Nicholas R Forsyth; Michael Heke; Liem Thanh Nguyen
Journal:  Signal Transduct Target Ther       Date:  2022-08-06

Review 3.  Emerging concepts in non-invasive monitoring of Crohn's disease.

Authors:  Wojciech Marlicz; Karolina Skonieczna-Żydecka; Konstantinos John Dabos; Igor Łoniewski; Anastasios Koulaouzidis
Journal:  Therap Adv Gastroenterol       Date:  2018-04-18       Impact factor: 4.409

Review 4.  Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies.

Authors:  Xiaoxiao Du; Sheng Chang; Wenzhi Guo; Shuijun Zhang; Zhonghua Klaus Chen
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.